WEDNESDAY, July 20, 2022 (HealthDay Information) — Hormone replacement therapy (HRT) for breast cancer survivors would not seem to extend the chance of cancer recurrence or demise, Danish researchers report.
Though HRT has beforehand been linked to a raised threat of breast most cancers’s return, these earlier research referred to oral HRT and never vaginal estrogen cream. The newest research, nonetheless, discovered no improve within the threat of recurrence or demise for girls getting both sort of HRT.
“These findings needs to be reassuring that using HRT shouldn’t be associated to any main dangers within the recurrence of breast most cancers or threat of demise for most girls,” mentioned lead researcher Dr. Soren Chilly, from the division of oncology at Odense College Hospital.
For girls taking aromatase inhibitors to decrease estrogen ranges, there’s a small threat of recurrence, however no elevated threat of demise, he famous.
Chilly added that whereas the research signifies short-term use of HRT for breast most cancers sufferers seems secure, long-term use could also be problematic.
In any case, he advises sufferers to have an in depth dialogue with their physician about utilizing HRT.
“It is one thing that you will have to debate along with your physician as a result of like all different remedies, there are professionals and cons,” Chilly mentioned. “You can’t say it is prohibited, however it’s a must to talk about it strongly along with your physician.”
For the research, Chilly and his colleagues collected knowledge on almost 8,500 ladies identified with early-stage breast most cancers between 1997 and 2004. These ladies acquired both no hormone treatment or 5 years of hormone remedy.
Among the many ladies who did not obtain vaginal estrogen remedy or menopausal hormone remedy earlier than a breast most cancers analysis, 1,957 used vaginal estrogen remedy and 133 used menopausal hormone remedy after their analysis.
Over a median of almost 10 years of follow-up, 16% had a recurrence of breast most cancers. In all, 111 sufferers who had a recurrence had acquired vaginal estrogen remedy, 16 had acquired menopausal hormone remedy, and about 1,200 ladies didn’t obtain both therapy.
The report was revealed July 20 within the Journal of the Nationwide Most cancers Institute .
Regardless of these findings, Dr. Brittany Zimmerman, a medical breast oncologist at Northwell Well being Most cancers Institute in Lake Success, N.Y., believes breast most cancers survivors must be cautious when utilizing HRT.
The unintended effects from estrogen deprivation after breast most cancers have an effect on many ladies and could be a main cause for discontinuing breast cancer treatments, similar to tamoxifen and aromatase inhibitors, she mentioned.
“As a medical oncologist, considered one of my principal roles is to assist sufferers handle signs of those medicines to enhance high quality of life, and assist sufferers stay on their breast cancer-directed therapies,” Zimmerman mentioned.
Many methods can be found to handle these unintended effects, together with hormonal and non-hormonal remedies.
“Usually, we keep away from estrogen-based hormonal therapies for sufferers with a previous historical past of breast most cancers based mostly on outcomes of prior research, which present an elevated threat of breast most cancers recurrence,” Zimmerman mentioned.
This research supplies an attention-grabbing new commentary about using vaginal estrogen remedy in sufferers with a historical past of breast most cancers, she mentioned.
“The research discovered a barely elevated threat of breast most cancers recurrence amongst sufferers who used vaginal estrogen remedy and have been taking aromatase inhibitors,” Zimmerman famous.
Earlier research have proven that vaginal estrogen is mostly secure in breast most cancers survivors and had very low estrogen absorption into the physique, she mentioned.
“I’d, nonetheless, suggest sufferers with vaginal signs similar to vaginal dryness or burning strive non-hormonal therapies earlier than utilizing vaginal estrogen remedy,” Zimmerman mentioned.
However “this determination needs to be made after dialogue with the affected person’s breast medical oncologist,” she added.
Whereas the brand new research suggests there isn’t a elevated threat of breast most cancers recurrence with oral hormonal remedy, a number of earlier research have advised an elevated threat, Zimmerman famous.
“I’d encourage all sufferers to debate using hormonal remedy for warm flashes with their medical oncologist and to restrict use whereas additional research are in course of,” she mentioned.
For extra on HRT and breast most cancers, head to the American Most cancers Society.
SOURCES: Soren Chilly, MD, division of oncology, Odense College Hospital, Odense, Denmark; Brittany Zimmerman, MD, medical breast oncologist, Northwell Well being Most cancers Institute, Lake Success, N.Y.; Journal of the Nationwide Most cancers Institute, July 20, 2022